Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.

Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges.

Aspirin has been a commercial drug for over a century, although for most of this history, an understanding of its mechanism of action, as an inhibitor of cyclooxygenase (COX) activity and thus of prostanoid synthesis, was lacking. Over the past fifty years, a large number of other nonsteroidal antii...

Bibliografski detalji
Glavni autori:	Patrono, C, Baigent, C
Format:	Journal article
Jezik:	English
Izdano:	2009

Slični predmeti

Coxibs and traditional NSAIDs for pain relief - Authors' reply.
od: Bhala, N, i dr.
Izdano: (2014)

Coxibs and traditional NSAIDs for pain relief - Authors' reply.
od: Bhala, N, i dr.
Izdano: (2014)

Review: NSAIDs increase GI and CV events; coxibs increase mortality
od: Baigent, C
Izdano: (2013)

Coxibs, traditional NSAIDs and cardiovascular safety post-PRECISION: What we thought we knew then and what we think we know now
od: Patrono, C, i dr.
Izdano: (2017)

Low-dose aspirin for the prevention of atherothrombosis.
od: Patrono, C, i dr.
Izdano: (2005)

Drug therapy - Low-dose aspirin for the prevention of atherothrombosis
od: Patrono, C, i dr.
Izdano: (2005)

ASA, NSAIDs, Coxibs and Colorectal Cancer Prevention — How Far Have We Come?
od: Martin Fishman
Izdano: (2004-01-01)

Antiplatelet therapy: aspirin for asymptomatic atherosclerosis?
od: Patrono, C, i dr.
Izdano: (2010)

Role of aspirin in primary prevention of cardiovascular disease
od: Patrono, C, i dr.
Izdano: (2019)

Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
od: Moore, R, i dr.
Izdano: (2006)

Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal.
od: Baigent, C, i dr.
Izdano: (2003)

Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice
od: Phillips Ceri J, i dr.
Izdano: (2006-10-01)

Pharmacoutilization of anti-inflammatory and gastroprotective drugs in patients with osteoarthritis: comparison between COXIBs and conventional NSAIDs by using administrative records
od: Luca Degli Esposti, i dr.
Izdano: (2006-01-01)

Gastric and renal effects of COX-2 selective and non-selective NSAIDs in rats receiving low-dose aspirin therapy
od: Marcella Goetz MORO, i dr.

Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease
od: Esha Sehanobish, i dr.
Izdano: (2021-06-01)

Results of the PRECISION study: Could an answer be given to the question of how safe coxibs versus traditional NSAIDs are in treating patients at high risk for cardiovascular events?
od: E. V. Dovgan
Izdano: (2017-09-01)

Cardiac toxicity of coxibs: mechanisms of development and their prevention
od: O O Yakovleva, i dr.
Izdano: (2018-11-01)

Opinion - Coxibs: can this class of drugs survive?
od: Reza Tabrizchi
Izdano: (2005-04-01)

COX-2 SPECIFIC INHIBITORS (COXIBS) CRISIS
od: Abbas Ali Mansour
Izdano: (2003-12-01)

What is safer for the gastrointestinal-tract: Coxibs or meloxicam?
od: A. M. Satybaldyev, i dr.
Izdano: (2017-03-01)

Pathogenesis of NSAID-induced reactions in aspirin-exacerbated respiratory disease
od: Tanya M. Laidlaw
Izdano: (2018-09-01)

NSAIDs, Mitochondria and Calcium Signaling: Special Focus on Aspirin/Salicylates
od: Yoshihiro Suzuki, i dr.
Izdano: (2010-05-01)

Rofecoxib-Induced Hepatotoxicity: A Forgotten Complication of the Coxibs
od: Brian Yan, i dr.
Izdano: (2006-01-01)

The adverse effects of different doses of aspirin: a systematic overview of randomised trials and observational studies
od: Sudlow, G, i dr.
Izdano: (2000)

Low-dose aspirin for migraine prophylaxis.
od: Buring, J, i dr.
Izdano: (1990)

COX-2 inhibitors and the heart: are all coxibs the same?
od: Sooriakumaran, P
Izdano: (2006)

Determination of the prevalence of clinical signs of Aspirin and NSAID poisoning in patients referring to Ahvaz Razi Hospital
od: Maryam Shirani, i dr.
Izdano: (2022-09-01)

Benefit of heparin plus aspirin vs aspirin alone in unstable angina.
od: Collins, R, i dr.
Izdano: (1996)

Aspirin for everyone older than 50? Against.
od: Baigent, C
Izdano: (2005)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
od: Dorien Van Broeck, i dr.
Izdano: (2023-04-01)

Faecal blood loss: Systematic review and analysis of randomised trials with aspirin and NSAIDs
od: Moore, A, i dr.
Izdano: (2007)

LOW-DOSE ASPIRIN IN PREGNANCY AND EARLY-CHILDHOOD DEVELOPMENT - FOLLOW-UP OF THE COLLABORATIVE LOW-DOSE ASPIRIN STUDY IN PREGNANCY
od: Farrell, B, i dr.
Izdano: (1995)

Aspirin for disease prevention: public policy or personal choice?
od: Baigent, C
Izdano: (2016)

Variability in aspirin efficacy: all in the genes?
od: Baigent, C, i dr.
Izdano: (2019)

Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
od: Baigent, C, i dr.
Izdano: (2002)

Farmacoeconomia dei COXIB nella patologia osteoarticolare: revisione della letteratura
od: Pierluigi Russo, i dr.
Izdano: (2003-05-01)

Aspirin, platelet inhibition and cancer prevention
od: Paola Patrignani, i dr.
Izdano: (2018-11-01)

Aspirin at 120: Retiring, recombining, or repurposing?
od: Carlo Patrono, i dr.
Izdano: (2021-05-01)

3437 Associations of aspirin, non-aspirin NSAIDs, statins, and metformin with risk of biliary cancer: A Swedish population-based cohort study
od: Lorena Marcano Bonilla, i dr.
Izdano: (2019-03-01)

Quality of Life in NSAIDs-Exacerbated Respiratory Disease on or off Intranasal Lysine Aspirin Therapy
od: Alfonso Luca Pendolino, i dr.
Izdano: (2024-01-01)